Furthermore, in AR+ tumors, some SARMs can act as partial agonists or even stimulate AR activity depending on the TME, co-regulator landscape, and ligand concentration, potentially promoting tumor progression [72,77]. The gene discussed is AR; the disease is neoplasm.